224 related articles for article (PubMed ID: 20835873)
1. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
Boccia RV; Gordan LN; Clark G; Howell JD; Grunberg SM;
Support Care Cancer; 2011 Oct; 19(10):1609-17. PubMed ID: 20835873
[TBL] [Abstract][Full Text] [Related]
2. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
3. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
Yang LQ; Sun XC; Qin SK; Chen YX; Zhang HL; Cheng Y; Chen ZD; Shi JH; Wu Q; Bai YX; Han BH; Liu W; Ouyang XN; Liu JW; Zhang ZH; Li YQ; Xu JM; Yu SY
Chin Clin Oncol; 2016 Dec; 5(6):79. PubMed ID: 28061543
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Kim JE; Hong YS; Lee JL; Kim KP; Park SJ; Sym SJ; Shin DB; Lee J; Park YS; Ahn JS; Kim TW
Support Care Cancer; 2015 Jun; 23(6):1769-77. PubMed ID: 25465680
[TBL] [Abstract][Full Text] [Related]
5. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.
Keating GM; Duggan ST; Curran MP
CNS Drugs; 2012 Sep; 26(9):787-90. PubMed ID: 22834568
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
7. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Armbruster SD; Fellman BM; Jhingran A; Eifel PJ; Klopp AH; Coleman RL; Ramondetta LM; Frumovitz M
Support Care Cancer; 2021 Jan; 29(1):213-222. PubMed ID: 32338316
[TBL] [Abstract][Full Text] [Related]
8. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
Coluzzi F; Mattia C
Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113
[TBL] [Abstract][Full Text] [Related]
9. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial.
Sun S; Ko YH; Jin JY; Woo IS; Park SY; Eom YA; Kang JH; Kim HK
Korean J Intern Med; 2023 May; 38(3):406-416. PubMed ID: 35263841
[TBL] [Abstract][Full Text] [Related]
12. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
16. Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis.
Chua AV; Hernandez ARB; Real IO
Support Care Cancer; 2020 Dec; 28(12):5611-5619. PubMed ID: 32623521
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting.
Howell J; Smeets J; Drenth HJ; Gill D
J Oncol Pharm Pract; 2009 Dec; 15(4):223-31. PubMed ID: 19304880
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
